FDA Approves New Therapeutic Treatment for Progressive Keratoconus
Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has received approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL System. Together, this new system represents a significant milestone in the treatment of keratoconus, a progressive eye disease that causes a thinning of the cornea. The KXL System
July 27, 2016
English